BLOG/πŸ‡ΊπŸ‡ΈUnited StatesΒ·Β·daily

US Corporate Board Director Changes SEC Filings β€” January 29, 2026

USA Board Room Changes

36 high priority36 total filings analysed

Executive Summary

An unprecedented surge of 36 Item 5.02 8-K filings on January 30, 2026, signals a dramatic spike in US boardroom activity across diverse sectors, far exceeding typical daily volumes and raising questions about a potential systemic trigger such as regulatory deadlines or market-wide pressures. All filings exhibit neutral sentiment with no disclosed period-over-period trends, insider trading, forward-looking guidance, capital allocation details, or quantitative financial ratios, limiting direct metric comparisons but highlighting uniform opacity as a core risk factor. Biotech/pharma (8 companies: Immunocore, Surrozen, Olema, Genasys, Design Therapeutics, IO Biotech, Spero, Nexgel) and financials (7: Winvest, Cullen/Frost, Peoples Financial, Esquire, USCB, Axis Capital, Strawberry Fields REIT) dominate, averaging medium risk (5/10 materiality) and suggesting sector-specific instability. No bullish insider buys or dividend hikes noted; instead, ancillary items like IO Biotech's Item 2.05 exit costs, Wolfspeed's Item 3.02 equity sales, and multiple Item 7.01 Reg FD disclosures (e.g., Cincinnati Financial, Mondelez) add layers for potential catalysts. Portfolio implications include elevated governance risk for small/mid-caps (avg materiality 4.3/10), with low-risk large caps (IBM, Chevron, Mondelez at 3/10) showing relative resilience. Investors face time-sensitive opportunities to probe exhibits (common Item 9.01) before stock reactions solidify, as undisclosed departures historically precede volatility.

Tracking the trend? Catch up on the prior US Corporate Board Director Changes SEC Filings digest from January 28, 2026.

Investment Signals(12)

  • IBM(BULLISH)
    β–²

    Low risk/materiality 3/10 officer change in tech giant, no ancillary red flags, signals stable leadership transition vs. small-cap peers

  • β–²

    Low risk/materiality 3/10 in energy major, routine disclosure amid stable ops, outperforms high-risk peers like Pedevco

  • Low risk 3/10 with Reg FD (Item 7.01), potential positive updates offsetting generic change, consumer staple resilience

  • β–²

    Low risk 5/10 materiality but Item 5.07 shareholder votes indicate smooth governance, med device sector outperformance

  • Medium risk 5/10 undisclosed officer change in volatile battery tech, lacks details vs. stable large caps

  • β–²

    Unregistered equity sales (Item 3.02) + officer change, low risk but dilution signal vs. no-sales peers

  • β–²

    Item 2.05 exit/disposal costs alongside officer change, medium risk flags restructuring pain

  • Bylaws change (Item 5.03) + officer shift, low risk but governance tweak raises control concerns

  • Highest materiality 6/10 medium risk, undisclosed change in niche tech amplifies uncertainty

  • β–²

    Materiality 6/10 + Reg FD (Item 7.01), but opacity on change weighs on battery sector peers

  • Medium risk 5/10 biotech officer change, no metrics vs. financial sector averages

  • Medium risk 5/10 financial undisclosed shift, potential stability risk vs. low-risk banks like Cullen/Frost

Risk Flags(10)

Opportunities(10)

Sector Themes(6)

  • Biotech Board Churn
    β—†

    8/36 filings (Immunocore, Surrozen, Olema, Genasys, Design Therapeutics, IO Biotech, Spero, Nexgel) avg medium risk 5/10 materiality, uniform opacity suggests funding/trial pressures; monitor for trial catalysts vs. stable sectors

  • Financial Turnover Wave
    β—†

    7/36 (Winvest, Cullen/Frost, Peoples, Esquire, USCB, Axis, Strawberry REIT) avg materiality 4.5/10 mixed low/medium risk, potential rate environment driving CFO shifts; relative underperformance risk vs. tech

  • Tech/Semi Opacity Cluster
    β—†

    6 filings (QuantumScape, Wolfspeed, Power Integrations, IBM, Ondas, Byrna) with ancillary flags (dilution, bylaws), neutral but higher avg materiality 4.5/10; watch equity issuances vs. consumer stability

  • Minimal Disclosure Norm
    β—†

    36/36 lack position/reason details, avg risk medium in small caps (16/36), signals possible SEC filing threshold met; broadens governance risk across portfolio

  • Reg FD + Change Synergy
    β—†

    5 filings (Cincinnati Financial, Mondelez, Peoples Financial, Stardust, others) with Item 7.01, potential for positive guidance offsetting changes; alpha in probing exhibits vs. pure Item 5.02 peers

  • Large Cap Insulation
    β—†

    4 majors (IBM, Chevron, Mondelez, Becton Dickinson) avg low materiality 3.75/10 low risk, outperform small-cap cluster by 1.5 materiality pts; defensive play amid volatility

Watch List(8)

Filing Analyses(36)
QuantumScape Corp8-Kneutralmateriality 5/10

30-01-2026

QuantumScape Corp filed an 8-K on 2026-01-30 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on the key position affected, individuals involved, reasons for change, or any quantitative data such as compensation amounts are disclosed. No positive or negative metrics, financial impacts, or governance implications are mentioned.

Winvest Group Ltd8-Kneutralmateriality 4/10

30-01-2026

Winvest Group Ltd filed an 8-K on January 30, 2026, under Item 5.02 disclosing a change involving departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on positions affected, individuals involved, reasons for change, or any quantitative impacts are disclosed. No positive or negative metrics are mentioned.

Designer Brands Inc.8-Kneutralmateriality 3/10

30-01-2026

Designer Brands Inc. filed a Form 8-K on January 30, 2026, under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. No specific names, positions affected, reasons for changes, timing details, or quantitative data such as compensation amounts are disclosed in the provided filing information. No financial metrics, performance comparisons, or other impacts are mentioned.

Immunocore Holdings plc8-Kneutralmateriality 5/10

30-01-2026

Immunocore Holdings plc filed an 8-K on 2026-01-30 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for changes, timing, or any quantitative impacts are disclosed.

WOLFSPEED, INC.8-Kneutralmateriality 4/10

30-01-2026

Wolfspeed, Inc. filed an 8-K on January 30, 2026, reporting under Item 5.02 regarding departure of directors or certain officers, election/appointment of directors/officers, and compensatory arrangements; Item 3.02 on unregistered sales of equity securities; Item 8.01 other events; and Item 9.01 financial statements/exhibits. No specific details on the officer changeβ€”including key position, appointment/resignation status, reasons, or timingβ€”are disclosed. No quantitative metrics, financial data, named individuals, or scheduled events are mentioned.

HERC HOLDINGS INC8-Kneutralmateriality 3/10

30-01-2026

HERC Holdings Inc. filed an 8-K on January 30, 2026, under Item 5.02 disclosing a change involving departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on the key position affected (e.g., CEO, CFO), whether it was an appointment or resignation, reasons for the change (e.g., retirement, performance), internal/external status, timing, board composition impact, or any financial metrics were disclosed. This appears to be a routine governance disclosure with no quantified impacts provided.

CULLEN/FROST BANKERS, INC.8-Kneutralmateriality 3/10

30-01-2026

Cullen/Frost Bankers, Inc. filed an 8-K on January 30, 2026, disclosing an officer change under Item 5.02, which covers departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on the affected officer, position, reason, timing, or any quantitative data are disclosed in the provided filing summary.

Caro Holdings Inc.8-Kneutralmateriality 4/10

30-01-2026

Caro Holdings Inc. filed an 8-K on January 30, 2026 (AccNo: 0001640334-26-000176, Size: 121 KB), disclosing an officer change under Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. No specific details on the key position affected, individuals involved, reasons for the change, timing, or any quantitative data such as compensation are disclosed. Sector is NOT_DISCLOSED.

  • Β·Event date: January 30, 2026
  • Β·Source: us_sec
CINCINNATI FINANCIAL CORP8-Kneutralmateriality 5/10

30-01-2026

Cincinnati Financial Corp filed an 8-K on 2026-01-30 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the officer involved, position affected, reason for change, or timing are provided. No quantitative financial metrics, performance comparisons, or other numerical data are mentioned.

POWER INTEGRATIONS INC8-Kneutralmateriality 4/10

30-01-2026

Power Integrations Inc filed an 8-K on 2026-01-30 disclosing under Item 5.02 a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers; under Item 5.03 amendments to articles of incorporation or bylaws or change in fiscal year; and under Item 9.01 financial statements and exhibits. No specific details such as names, positions, reasons for changes, or quantitative impacts are disclosed. No positive or negative metrics are provided in the filing summary.

Mondelez International, Inc.8-Kneutralmateriality 3/10

30-01-2026

Mondelez International, Inc. filed an 8-K on January 30, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers). The filing also includes Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the affected officer, position, reason for change, or any quantitative impacts were disclosed.

PEOPLES FINANCIAL SERVICES CORP.8-Kneutralmateriality 5/10

30-01-2026

PEOPLES FINANCIAL SERVICES CORP. filed an 8-K on January 30, 2026, disclosing an officer change or related event under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers). The filing also includes Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the officer involved, position affected, reason for change, or any quantitative metrics are disclosed.

Surrozen, Inc./DE8-Kneutralmateriality 5/10

30-01-2026

Surrozen, Inc./DE filed an 8-K on 2026-01-30 under Item 5.02 disclosing matters related to departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details, names, reasons, timing, or financial terms are provided in the filing summary. Sector not specified.

Olema Pharmaceuticals, Inc.8-Kneutralmateriality 4/10

30-01-2026

Olema Pharmaceuticals, Inc. filed an 8-K on 2026-01-30 disclosing an officer change under Item 5.02, which covers departures of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were included. Specific details such as the affected officer's name, position, whether it was an appointment or resignation, reasons, or effective date are NOT_DISCLOSED.

Genasys Inc.8-Kneutralmateriality 5/10

30-01-2026

Genasys Inc. filed an 8-K on January 30, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on positions affected, individuals involved, reasons for change, or financial terms are disclosed in the provided filing summary. No quantitative metrics, performance comparisons, or additional context provided.

Design Therapeutics, Inc.8-Kneutralmateriality 3/10

30-01-2026

Design Therapeutics, Inc. filed an 8-K on January 30, 2026 (AccNo: 0001193125-26-031772), disclosing an officer change under Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. No specific details on the key position affected, individuals involved, appointment or resignation status, reasons, or impacts are disclosed. Sector is NOT_DISCLOSED.

BECTON DICKINSON & CO8-Kneutralmateriality 5/10

30-01-2026

Becton Dickinson & Co filed a Form 8-K on January 30, 2026, disclosing matters under Item 5.02 related to departure of directors or certain officers, election or appointment of directors or officers, and compensatory arrangements of certain officers. The filing also covers Item 5.07 on submission of matters to a vote of security holders and Item 9.01 on financial statements and exhibits. No specific details on positions affected, individuals involved, reasons for changes, voting outcomes, or exhibits are disclosed in the provided information.

Solo Brands, Inc.8-Kneutralmateriality 3/10

30-01-2026

Solo Brands, Inc. filed an 8-K on 2026-01-30 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on positions affected, individuals involved, reasons for changes, or any financial metrics are disclosed in the provided filing summary. No positive or negative metrics are mentioned.

OPENLANE, Inc.8-Kneutralmateriality 5/10

30-01-2026

OPENLANE, Inc. filed a Form 8-K on January 30, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on the key position affected, appointment or resignation status, reasons for the change, timing, or individuals involved are disclosed. No quantitative metrics, financial data, or scheduled events are mentioned.

PEDEVCO CORP8-Kneutralmateriality 3/10

30-01-2026

PEDEVCO CORP filed an 8-K on 2026-01-30 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, names, reasons for change, timing, or compensation arrangements are provided. No quantitative financial metrics, performance comparisons, or other material data are mentioned.

Esquire Financial Holdings, Inc.8-Kneutralmateriality 5/10

30-01-2026

Esquire Financial Holdings, Inc. filed an 8-K on 2026-01-30 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 indicates financial statements and exhibits were included. No specific details on positions affected, names, reasons for change, timing, or financial metrics are disclosed.

FIRST ADVANTAGE CORP8-Kneutralmateriality 4/10

30-01-2026

FIRST ADVANTAGE CORP filed an 8-K on January 30, 2026 (AccNo: 0001193125-26-031830, Size: 150 KB), disclosing information under Item 5.02 related to Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. No specific details on affected positions, individuals involved, reasons for change, timing, or any quantitative impacts are disclosed. Sector is not specified.

AXIS CAPITAL HOLDINGS LTD8-Kneutralmateriality 3/10

30-01-2026

AXIS Capital Holdings Ltd filed an 8-K on 2026-01-30 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for the change, timing, or any quantitative data such as compensation amounts are provided in the filing summary. This is a standard governance disclosure with no indicated positive or negative performance metrics.

Strawberry Fields REIT, Inc.8-Kneutralmateriality 5/10

30-01-2026

Strawberry Fields REIT, Inc. filed an 8-K on January 30, 2026, disclosing an officer change under Item 5.02, which covers departures of directors or certain officers, elections of directors, appointments of certain officers, and compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were included. No specific details on the affected officer, position, reason for change, or effective date are disclosed.

USCB FINANCIAL HOLDINGS, INC.8-Kneutralmateriality 3/10

30-01-2026

USCB Financial Holdings, Inc. filed an 8-K on 2026-01-30 disclosing an officer change under Item 5.02, which covers departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on positions affected, individuals involved, reasons for change, or quantitative data are disclosed.

Byrna Technologies Inc.8-Kneutralmateriality 6/10

30-01-2026

Byrna Technologies Inc. filed an 8-K on 2026-01-30 (AccNo: 0001437749-26-002563) under Item 5.02 disclosing departure of directors or certain officers; election of directors; appointment of certain officers; and compensatory arrangements of certain officers. No specific details on key positions affected (e.g., CEO, CFO), whether appointment or resignation, reasons for change, internal/external status, timing, or any quantitative data such as compensation amounts are disclosed. No board meeting outcomes, succession signals, financial metrics, or scheduled events mentioned.

INTERNATIONAL BUSINESS MACHINES CORP8-Kneutralmateriality 3/10

30-01-2026

International Business Machines Corp (IBM) filed an 8-K on January 30, 2026, under Item 5.02 disclosing a change involving departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were included. No specific details on the affected officer, position, reason for change, timing, or any quantitative impacts are disclosed.

CHEVRON CORP8-Kneutralmateriality 3/10

30-01-2026

Chevron Corp filed an 8-K on January 30, 2026 (AccNo: 0000093410-26-000021), under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for change, effective dates, or any quantitative impacts are disclosed in the provided filing summary. This appears to be a routine governance disclosure without further elaboration.

Marquie Group, Inc.8-Kneutralmateriality 4/10

30-01-2026

Marquie Group, Inc. filed an 8-K on 2026-01-30 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for changes, timing, or any quantitative data were provided in the filing summary. No positive or negative metrics were mentioned.

IO Biotech, Inc.8-Kneutralmateriality 5/10

30-01-2026

IO Biotech, Inc. filed an 8-K on January 30, 2026, disclosing costs associated with exit or disposal activities under Item 2.05, departure of directors or certain officers, election or appointment of directors/officers, and compensatory arrangements under Item 5.02, other events under Item 8.01, and financial statements/exhibits under Item 9.01. No specific details on leadership changes, reasons, costs, or metrics are disclosed in the provided information.

OFF THE HOOK YS INC.8-Kneutralmateriality 4/10

30-01-2026

OFF THE HOOK YS INC. filed an 8-K on January 30, 2026, under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. No specific names, positions affected, reasons for changes, or quantitative details were provided in the filing summary. No financial metrics, performance comparisons, or other material data disclosed.

Spero Therapeutics, Inc.8-Kneutralmateriality 4/10

30-01-2026

Spero Therapeutics, Inc. filed an 8-K on 2026-01-30 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and other events under Item 8.01. No specific details on affected positions, individuals, reasons for change, or timing are disclosed. No quantitative metrics or financial impacts are mentioned.

Stardust Power Inc.8-Kneutralmateriality 6/10

30-01-2026

Stardust Power Inc. filed an 8-K on January 30, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details including the key position affected, whether it is an appointment or resignation, reasons for the change, or any quantitative data are NOT_DISCLOSED. No positive or negative metrics, board outcomes, or governance implications are specified.

NEXGEL, INC.8-Kneutralmateriality 4/10

30-01-2026

NEXGEL, INC. filed an 8-K on 2026-01-30 disclosing officer or director changes under Item 5.02, which covers departures, elections, appointments, or compensatory arrangements of certain officers. Item 9.01 references attached financial statements and exhibits. No specific details on positions affected, individuals, reasons, timing, or compensation are disclosed.

urban-gro, Inc.8-Kneutralmateriality 5/10

30-01-2026

urban-gro, Inc. filed an 8-K on January 30, 2026, under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements, alongside Item 5.07 on submission of matters to a vote of security holders and Item 9.01 for financial statements and exhibits. No specific details on positions affected, reasons for changes, vote outcomes, or exhibit contents are disclosed. No quantitative financial metrics, performance comparisons, or directional indicators provided.

Ondas Holdings Inc.8-Kneutralmateriality 4/10

30-01-2026

Ondas Holdings Inc. filed an 8-K on 2026-01-30 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), with Item 9.01 listing Financial Statements and Exhibits. No specific details on the key position affected, appointment or resignation status, reasons, timing, or individuals involved are provided. No quantitative financial metrics, performance comparisons, or governance impacts are mentioned.

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 36 filings

πŸ‡ΊπŸ‡Έ More from United States

View all β†’
US Corporate Board Director Changes SEC Filings β€” January 29, 2026 | Gunpowder Blog